THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Vertex pays CEO $19.3m in 1st year

Money-losing biotech has no drugs on market

Matthew W. Emmens (left) replaced Joshua Boger as CEO of Vertex last May. The firm has not yet turned a profit. Matthew W. Emmens (left) replaced Joshua Boger as CEO of Vertex last May. The firm has not yet turned a profit.
By Todd Wallack
Globe Staff / April 16, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size – +

Another rookie Bay State chief executive is starting off with a massive pay package. Vertex Pharmaceuticals Inc. disclosed late yesterday that it gave new CEO Matthew W. Emmens $19.3 million in compensation last year, mostly in stock options that will vest over the next few years. (Full article: 409 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 article
  • $9.95 4 articles
  • $25.95 Monthly